If you're interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk. That's not a bad strategy since these two ...

The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...

Cipla Limited is planning to enter the weight management segment in India, announced the company’s MD and global CEO Umang ...

Mumbai: Mumbai-based pharma giant Cipla is gearing up to make an entry into India's rapidly growing weight management market, ...

The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and ...

Pharmaceutical giant Cipla plans to enter India's weight management sector, while also bolstering its central nervous system ...

Cipla expands into CNS and weight management segments, focusing on patient needs and innovation for long-term value.

Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said.